Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DDX11 siRNA
- Development stage
- Preclinical
- Lead developer
- University of Naples Federico II
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
DDX11 siRNA is an experimental RNA interference (RNAi) therapeutic agent designed to silence the expression of the DEAD-box helicase 11 (DDX11) gene, also known as ChlR1. DDX11 is a DNA helicase that plays a pivotal role in maintaining genome stability through its involvement in sister chromatid cohesion, DNA replication, and the repair of DNA interstrand cross-links. In various cancers, such as melanoma and osteosarcoma, DDX11 is frequently overexpressed, contributing to tumor cell proliferation, survival, and resistance to DNA-damaging therapies. By utilizing the RNA-induced silencing complex (RISC), DDX11 siRNA guides the sequence-specific cleavage of DDX11 mRNA, resulting in reduced protein levels. This knockdown induces DNA damage, cell cycle arrest, and apoptosis, making it a subject of preclinical investigation as a potential antineoplastic strategy.
- Other names
- DEAD-box helicase 11 siRNAChlR1 siRNAChlR-1 siRNAChlR 1 siRNAsi-DDX11si-DDX-11si-DDX 11DDX11-siRNADDX-11-siRNADDX 11-siRNA
02
Targets
DDX11 (DEAD-box helicase 11)
Beyond the preview
Go deeper on DDX11 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DDX11 siRNA.